OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Médico del ensayo/Coordinador del estudio
Kien Nguyen
Correo electrónico Número de teléfono (206) 676-0886OMS721 for Patients with IgAN
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN.
Criterios de elegibilidad
Población de pacientes
IgA Nephropathy
Sobre el medicamento o la intervención
Qué implica para el paciente
Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.
Nombre del patrocinador
Omeros Corporation
Matrícula estimada
430
Fecha estimada de finalización
April 2023
Sobre el estudio
Nombre del fármaco del estudio
OMS721
Objetivo del estudio
To determine if OMS721 reduces proteinuria in patients with IgAN.
Sobre el medicamento o la intervención
MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system.